JMM Correspondence
Salmonella enterica serovar Typhi strain producing extendedspectrum b-lactamases in Dhaka, Bangladesh
Various types of extended-spectrum blactamases (ESBLs) that confer resistance to oxyimino-b-lactam antibiotics (cephalosporins) are an emerging threat and of great concern worldwide. These enzymes are most frequently isolated in Klebsiella pneumoniae and Escherichia coli; however, in recent years, the growing incidence of ESBLs in other members of the family Enterobacteriaceae, including different serovars of Salmonella enterica, has been documented (Cantó n et al., 2008; Gniadkowski, 2001; Pardos de la Gándara et al., 2011; Pokharel et al., 2006) . Salmonella enterica serovar Typhi (S. Typhi), the causative agent of typhoid fever, can cause a severe systemic infection associated with high rates of morbidity and mortality, especially in children and immunocompromised hosts, and in these cases, antimicrobial therapy is recommended (Threlfall, 2002) . The fatality rates from typhoid fever have been reduced greatly in developed countries through effective antimicrobial therapy, along with proper sanitation and hygiene practices; however, the recent increase in drug resistance in developing countries like Bangladesh is of concern (Ahmed et al., 2006; Pokharel et al., 2006; Stephen et al., 2003) . High-level ceftriaxone resistance in an S. Typhi isolate has been reported previously from Bangladesh (Saha et al., 1999) . Recently, the production of the SHV-12 ESBL by an S. Typhi isolate from the Philippines was reported (Al Naiemi et al., 2008) . Here, we report what we believe to be the first isolation of ESBLproducing S. Typhi in Bangladesh.
The strain was isolated from a boy aged 3 years and 10 months with recurrent onset of high-grade fever (105 u F) following 8 days of treatment with ceftriaxone (1 g per day) and positive Widal test. The fever recurred on the 10th day after the last dose of ceftriaxone. A blood sample was sent for culture and the isolated strain showed resistance to extended-spectrum cephalosporins (ESCs) and other commonly used antibiotics during routine antimicrobial susceptibility testing. We investigated whether the resistance to ESCs was due to the production of ESBLs, and further analysis confirmed the production of the ESBLs CTX-M and TEM by this isolate. Later the patient was given azithromycin (20 mg kg 21 per day) for 14 days and he became afebrile on the fifth day of treatment. None of the family members had a recent history of suffering from typhoid fever.
Blood culture using BacT/ALERT 3D (bioMérieux) revealed an S. Typhi isolate. The strain was identified by conventional biochemical and API 20E (bioMérieux) tests and serogrouped using commercially available antisera (Denka Seiken). Antimicrobial susceptibility testing was performed according to the Clinical and Laboratory Standards Institute guidelines (CLSI, 2008) by the disc diffusion method. MICs were determined by Etest according to the manufacturer's instructions (AB Biodisk). ESBL production was detected by the combined disc test and ESBL Etest (AB Biodisk) (Livermore & Brown, 2001) . To detect the genes encoding ESBLs, PCR experiments were performed with bla CTX-M , bla TEM , bla SHV and bla OXA gene specific primers. PCRs were run as described previously (Edelstein et al., 2003; Lal et al., 2007) .
The strain showed resistance to ampicillin, cefixime, cefotaxime, ceftazidime, ceftriaxone, chloramphenicol, nalidixic acid and trimethoprim-sulfamethoxazole and was susceptible to other tested drugs ( (Baraniak et al., 2002) . The ESBL genes are mostly plasmid-encoded, and CTX-M and TEM (molecular class A) are the most frequently encountered ESBLs in Salmonella species, as in other members of the Enterobacteriaceae. ESBL production has been observed in different serovars of S. enterica, and recently an S. Typhi strain originating from the Philippines (Al Naiemi et al., 2008) was the first to be reported as an ESBL producer. However, to our knowledge, this is the first report of ESBL production by an S. Typhi isolate here in Dhaka, Bangladesh. Sequencing and further geno-and subtyping is warranted for this isolate.
Typhoid fever is a major systemic health problem worldwide with an annual incidence of 22 million people and over 216 000 deaths, and it continues to be a major public health problem in developing countries (Crump et al., 2004) . A large incidence of childhood mortality with multidrug-resistant (MDR) strains of S. Typhi has been reported previously. A total of 57 % MDR S. Typhi strains were isolated at a referral centre in Dhaka in 2005 (Ahmed et al., 2006) . This emergence and predominant distribution of MDR S. Typhi could reflect the increasing cost of therapy (Bavdekar, 1996) . In addition, because of the increasing rates of resistance to ampicillin, trimethoprim-sulfamethoxazole and fluoroquinolones, ESCs are still the current drugs of choice for treating systemic Salmonella infections in Bangladesh. The emergence of ESBLproducing S. Typhi reflects the growing challenge towards the treatment of MDR typhoid cases. Dissemination of the resistance trait by mobile genetic elements, and the rapid emergence of an increase in resistance among the enteric bacteria, support the need for a vaccine and implementation of screening procedures for potential ESBL-producing Salmonella strains in Bangladesh. 
